Mortality of prematurely born newborns with respiratory distress syndrome received alpha poractant

Abstract

Research objective: to estimate efficiency of treatment with alpha proctant of prematurely born newborns with respiratory distress syndrome and to define possibilities of its increase on the example of obstetrical establishments of Azerbaijan.
Materials and methods of research: during 2014-2015 with the permission of The Ministry of Health of Azerbaijan Republic were used 1300 ampoules "Curosurf" (CheisiFarma-ceuficiSpA, Parma, Italy). The ampoule of 1,5 ml contains 120g of alpha proctant. The indication for use of "Curosurf" was prematurity of the newborn with the diagnosis of respiratory distress syndrome. The prematurely born newborn with congenital malformations, congenital pneumonia, neonatal aspiration syndromes, patrimonial trauma were not appointed "Curosurf". The received results. Relative smaller level of lethality is noted in Republic, Sheki regional, and Gandja perinatal centers. Statistically significantly high level of lethality of children is noted in Baku center of health (66,7±7,3%), Sabirabad (40,0±12,7%) and Guba regional centers (57,5±7,8%), maternity hospital No. 5 of Baku city (52,6±11,5%). The general level of lethality among newborns with respiratory distress syndrome of the joint-stock company to an introduction result "Curosurf" of therapy made 25,3±1,7% (95% a confidential interval of 21,9-28,7%).
Conclusions. The use of alpha proctant for treatment of prematurely born newborns with respiratory distress syndrome allows to keep life on average of 74,7±1,7% of patients. The effect of treatment with alpha proctant depends on the mass of fetus at the birth (the best result is received weighing fetus of 1500-1999 grams), on type of obstetrical establishment (the best result is received in the Republic prenatal center). Dependence of mortality risk of newborns with respiratory distress syndrome against treatment with the alpha proctant from the mass of a fetus causes need of use of the mortality rates standardized on body weight while comparing results of treatment.